Livongo Health is preparing for a $1 billion initial public offering this year, according to a new report from The Wall Street Journal.
The IPO for the Mountain View, Calif.-based diabetes-focused digital health company is set to drop in the third quarter of this year, according to the report.
Livongo tapped Morgan Stanley, Goldman Sachs Group and JPMorgan Chase & Co. as underwriters for the offering, according to The Wall Street Journal.
The company has raised approximately $240 million so far, and was recently given an $800 million valuation, according to the report.
Last September, Livongo Health said that it now integrates continuous glucose data from Abbott‘s (NYSE:ABT) FreeStyle Libre Pro system into its Livongo for Diabetes system, touting it as the first such system to integrate data from Abbott’s FreeStyle Libre Pro.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.